Novo Nordisk to license experimental GLP-1 pill from China's Hengrui

Technology By Reuters • September 29, 2026, 7:26 AM UTC
⏱ 1 min read 👁 4 views
Direct Source Verification: This story is aggregated from Reuters (reuters.com). Full reporting rights and copyright belong to the primary publisher.
Read on Reuters ↗
Novo Nordisk to license experimental GLP-1 pill from China's Hengrui  Reuters
Novo Nordisk to license experimental GLP-1 pill from China's Hengrui  Reuters
Original Source
https://www.reuters.com/legal/litigation/chinas-hengrui-inks-up-26-billion-deal-with-novo-nordisk-obesity-drug-2026-09-29/
Visit Reuters ↗
SHARE STORY:
𝕏 f in

Related Coverage in Technology